



DEvaluation of a new hybrid technique for closure of muscular
ventricular septal defects in a long-term setting
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Objective: Therapy for muscular ventricular septal defects beyond themoderator band, especially in neonates and
infants, has always been challenging for both surgeons and cardiologists. Recently, we established a patch closure
hybrid therapy for muscular ventricular septal defects. In this study, we evaluated it in a long-term porcine model.
Methods: Thirteen minipigs underwent anterolateral thoracotomy to expose the left ventricle. Muscular ventric-
ular septal defects were created under 2- and 3-dimensional echocardiographic guidance with a 7.5-mm sharp
punch instrument. Closure of the defects was undertaken with our new patch system in hybrid technique. Animals
were observed for 3 months. Echocardiographic evaluation and pathologic examination, including immunohis-
tochemical staining, were undertaken.
Results: Defects were successfully created in 12 pigs and closed in 10 pigs. Seven survived for 3 months. Re-
sidual shunting was noticed in 1 animal. Neither left ventricular dysfunction nor relevant damage to the valves
could be detected. Pathologic examination showed complete endothelialization of the patch and the nitinol an-
chors without protruding parts of the system. Cellular organization was proceeding. Immunohistochemical stain-
ing demonstrated endothelial cells on the surface of the patch and fibromuscular cells around the patch.
Conclusion: Our hybrid therapy was efficacious in closing muscular ventricular septal defects without impair-
ment of cardiac function. The patch system and nitinol anchors demonstrated good integration into the septum.
Further development of the system for human application is already being undertaken.Earn CME credits at
http://cme.ctsnetjournals.org
Hybrid therapy, which combines surgical and interventional
techniques, is a new, innovative approach for the treatment of
complex congenital malformations. Although each of these
techniques alone is limited, collaboration between surgeons
and cardiologists may enable complex procedures that could
not be attempted independently. Early experience has shown
that hybrid therapymay reduce operative times, decrease proce-
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pulmonarybypass (CPB), and improveprocedural outcomes.1-3
Therapy for muscular ventricular septal defects (mVSDs)
beyond the moderator band is still challenging. Both surgical
and interventional strategies for mVSD closure are still prob-
lematic. Reoperation rates as great as 10% have been reported
after surgery.4-6 Further, surgery requires the use of CPB,
which may be associated with neurologic complications7,8
or the development of a systemic inflammatory response syn-
drome.9 Interventions can be limited by poor vascular access,
low patient weight, and rhythm disturbances.1,10,11
Hybrid therapy seems to be a new option for treatment of
mVSDs. Several authors have reported on off-pump closure
of mVSDs with an Amplatzer device (AGA Medical Corp,
Plymouth, Minn) through a perventricular approach.1,12,13
They have reported advantages relative to open repair, in-
cluding avoidance of transection of the moderator band
or other right ventricular muscle bundles without the limita-
tions of vascular access or patient weight.12 They have also,
however, reported valve injuries, device embolization into
the aorta, rhythm disturbances, and device migration.1,13
Recently, we published a hybrid technique for patch
closure of mVSDs from the left ventricle (LV).14 Efforts
to establish a monodisk system for closure of cardiac septal
defects have been made before.15 In principle, a patch deliv-
ery device consisting of a polyester patch and a nitinol frame
was passed through the carotid artery into the LV. Thereaf-
ter, the patch was fixed with 8 to 10 nitinol anchors through
LV puncture with a specially designed stapler system.ardiovascular Surgery c Volume 138, Number 2 365
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
FS ¼ fractional shortening
LV ¼ left ventricle
mVSD ¼ muscular ventricular septal defect
PAP ¼ pulmonary arterial pressure
PCWP ¼ pulmonary capillary wedge pressure
SEM ¼ scanning electron microscopy
Closure was done under echocardiographic and fluoroscopic
control. Finally, the nitinol frame was detached from the
patch. In short-term porcine model, we demonstrated the
general feasibility of this technique.16 In this study, we re-
port our results on the evaluation of this technique in
a long-term porcine model in which residual shunting, de-
velopment of LV dysfunction, and integration of the patch
into the septum were especially addressed.
MATERIALS AND METHODS
Animals
Thirteen Go¨ttingen minipigs (Ellegaard Go¨ttingen Minipigs
A/S<Dalmose, Denmark) of either sex (20–30 kg) were used in an exper-
imental protocol that was approved by the local Governmental Commission
on the Care and Use of Animals (n¼ 13). They received care in compliance
with the Guide for the Care and Use of Laboratory Animals (www.nap.edu/
catalog/5140.html). Experiments were performed in the laboratory of surgi-
cal research, Walter Brendel Center for Experimental Medicine, at the
Ludwig Maximilians University of Munich.
Anesthesia and Surgical Preparation
Anesthesia and surgical preparation were performed as described
previously.14,16 Briefly, the right-sided carotid artery and jugular vein
were surgically exposed, and the artery was cannulated with a 9F introducer
sheath and the vein with an 11F introducer sheath. Arterial pressure and cen-
tral venous pressure were measured continuously. At 1-month follow-up the
left-sided external carotid artery and the jugular vein, and at 3 month follow-
up the femoral vein and artery were used for arterial and venous access.
Afterward, a left thoracotomy in the fifth or sixth intercostal space was per-
formed. After opening of the pericardium the heart was exposed. The entire
procedure was carried out without CPB. Two Teflon-armed, purse-string su-
tures were applied on the LV wall for instrument insertion.
Creation of mVSDs
Creation of mVSDs was achieved under 2- and 3-dimensional echocar-
diographic guidance, as described previously.16 For 2-dimensional echocar-
diography (Sonos 5500; Philips Healthcare Nederland BV, Eindhoven, The
Netherlands), a 5-MHz transesophageal echocardiographic probe was
placed behind the heart through an additional incision in the sixth intercostal
space. Epicardial real-time 3-dimensional echocardiography was performed
with the X7-2 matrix transducer of the iE33 Ultrasound System (Philips
Healthcare). Successful mVSD creation was confirmed by echocardiogra-
phy and by oximetric measurement of the shunt volume by the Fick method.
Closure of mVSDs and Follow-up
The patch delivery device and the custom-designed stapler for fixation
have been described in earlier publications.14,17,18 During the study period,
we modified the stapler and introduced a 2-step releasing system for better
preventionof anchor embolism.Apause in thefixation process occurs shortly
before the forceps inside the stapler releases the nitinol anchor, so that the op-
erator can ensure that the nitinol anchor is still in right position and is well
fixed in the tissue. The nitinol anchor is then released in a second step. Clo-
sure of the mVSDs was undertaken as described previously.14 Briefly, the
patch delivery device was inserted into a custom-designed, 30-cm long 7F
sheath. It was forwarded over a 6F pigtail catheter through the 9F introducer
sheath across the carotid artery into the LV. The patch was deployed and po-
sitioned over the defect under fluoroscopic and echocardiographic guidance.
The custom-designed stapler was introduced through a 7F sheath inside the
lateral LV wall. Subsequently, the patch was fixed with 8 to 10 nitinol mini-
anchors under epicardial 3- and 2-dimensional echocardiographic andfluoro-
scopic guidance. After fixation was secured, the nitinol frame was detached
from the polyester patch by releasing the sutures (Figure 1) and was drawn
back into the long 7F sheath. Figure 1 shows the essentials of our therapy
and an ex vivo demonstration of the main principle of our technique.
Follow-ups were undertaken after 1 and 3 months. All animals received
aspirin for 3 months.
Hemodynamic Measurements and
Echocardiography
Heart rate, arterial pressure, and central venous pressure were measured
and recorded periodically. The following hemodynamic parameters were
measured as baseline before thoracotomy: central venous pressure, pulmo-
nary arterial pressure (PAP), and pulmonary capillary wedge pressure
(PCWP). Initial echocardiography was performed to exclude heart defects
and to determine the basal fractional shortening (FS). After shunt creation
and closure of the defects, the same hemodynamic parameters were mea-
sured. Blood samples were taken to measure shunt volume. Echocardiogra-
phy was used to assess the diameter of the mVSD.
After defect closure, echocardiography was performed to detect potential
residual shunts and valve insufficiencies. Additionally, residual shunt vol-
ume was determined by measuring required hemodynamic parameters.
At follow-up, arterial pressure, central venous pressure, PAP, and PCWP
were measured, and detailed echocardiography was done to evaluate cardiac
function, especially to investigate valve function and insufficiencies. Mea-
surements of FS and stress echocardiography with dobutamine (Fresenius-
Kabi, Bad Homburg, Germany) were performed to quantify cardiac
function. Residual shunts were estimated from echocardiographic and he-
modynamic measurements.
Pathologic Studies
Tissue preparation. After the 3-month follow-up, animals were
killed by intracardiac injection of 40 mEq potassium chloride (Braun, Mel-
sungen, Germany). After explantation of the heart, macroscopic evaluation
and documentation were performed. The tissue block containing the patch
and the anchors was dissected with a minimum of surrounding tissue.
After brief flushing with saline solution, specimens were fixed in forma-
lin (buffered 4%) and prepared for histologic and immunohistochemical ex-
amination. For scanning electron microscopy (SEM), part of the specimen
was placed in glutaraldehyde (2.5%).
Embedding, sectioning, andhistologic examination. After
fixation, most of the tissue block was embedded in methyl methacrylate
resin (Technovit 9100; Kulzer & Co,Wehrheim, Germany).19 After harden-
ing, the resin blocks were subsequently sectioned in slices of 0.8 mm with
a diamond band saw (300 CP; Exakt GmbH, Norderstedt, Germany). The
slices were ground down to 5 to 30 mm with a horizontal rotating grinder
and polisher (400 CS; Exakt). Staining of resin-embedded specimens was
performed with Richardson blue.
Immunohistochemical staining. Preparation of the sections for
immunohistochemical staining was performed with deplastification of the
tissue and mounting on glass slides.20 Binding of primary antibodies was
detected with horseradish peroxidase–conjugated secondary antibodies.
366 The Journal of Thoracic and Cardiovascular Surgery c August 2009
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DFIGURE 1. Principle of hybrid therapy. A through C, Polyester patch and delivery system; D, stapler; E, stapler tip with nitinol anchor. F, Patch delivery
device is put on piece of muscular septum. G and H, Fixation of nitinol minianchor onmuscular septumwith custom-designed stapler. I, Fixation of patch with
7 nitinol minianchors. J, After release of sutures, nitinol frame detaches from patch. K, Patch remains in muscular septum with nitinol minianchors.The sections were counterstained with hemalaun. We used antibodies
against von Willebrand factor for identification of endothelial cells. Anti-
bodies against smooth muscle actin and vimentin were used for analysis
of cellular components of the newly formed tissue within the closed septal
defect and around the device.
Scanning electron microscopy. Part of the specimen was
prepared for SEM and placed in glutaraldehyde (2.5%) for fixation. Images
were obtained after critical-point drying and gold coating of the specimen.
Scanning electron microscope (Zeiss DSM 940; Carl Zeiss NTS GmbH,
Oberkochen, Germany) was used for examination.
Statistical Analysis
Values are presented as mean SD. For comparison of different groups,
the paired t test was used.
RESULTS
Creation and Closure of mVSDs
Creation of mVSDs under echocardiographic guidance
was successful in 12 of 13 animals. The mean size of the cre-
ated mVSDs, as determined by 2-dimensional echocardiog-
raphy, was 5.0 0.8 mm. Shunt volumes ranged from 13%
to 54% (mean 20.1%). The defects were located in the api-
cal (n ¼ 3), midmuscular (n ¼ 6), anterior (n ¼ 2), and in-
ferior (n ¼ 1) septum.
Successful closure of the defects was achieved in 10 of 12
animals (Table 1). Animal 2 had to be killed at the end of the
experiment after failure of patch implantation; the patch was
located inside themVSDand therefore did not close it. Further-
more, the papillarymuscles of the tricuspid valve were injured
by 2 anchors. Animal 10 died of bleeding at the LV.Macropa-
thologic examination showed correct placement of the patch.
Follow-up
Long-term follow-up was done for 10 animals (Table 1).
Seven of 10 animals survived for 3 months. Animal 4 diedThe Journal of Thoracic and Cof lung edema after successful implantation of the patch.
The death of animal 9 was considered to be related to our
technique. In this case, macropathologic examination re-
vealed that 2 anchors had captured one septal attachment
of the tricuspid valve. The patch itself was placed properly.
Postprocedural echocardiography showed no impairment of
the tricuspid valve. Animal 12 died of a pneumothorax on
postoperative day 14. Two animals had postprocedural
pneumonia, which was successfully treated with antibiotics.
In animal 3, small residual shuntingwas seen on echocardi-
ography (Table 1). The animal experiment was not terminated
throughout the observation period. Pathologic examination
revealed a small dehiscence at the border of the patch.
No clinical evidence of thromboembolic events was
found in any of the animals. We found that 2 anchors had
embolized into the lung in one animal; this was confirmed
with radiographic evaluation at 1-month follow-up. Clinical
symptoms caused by embolization were not seen.
Hemodynamics
Pigs were in hemodynamically stable condition at all time
points and received no catecholamines during creation and
closure of mVSDs. There was a statistically significant in-
crease in PAP after creation of the mVSD (from 17.7 
4.3 to 27.7 2.9 mm Hg, P<.05), which decreased contin-
uously after closure. A slight elevation in PAP remained af-
ter 3 months. PCWP also increased after creation of the
defects (from 10.3  4.2 to 15.8  4.8 mm Hg, P< .05),
but PCWP decreased to baseline values during follow-up.
Echocardiography
Relevant echocardiographic data collected during mVSD
closure and at follow-up are summarized in Table 1.ardiovascular Surgery c Volume 138, Number 2 367
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premature death Preoperative Follow-up, 1 mo Follow-up, 3 mo
1 Midmuscular, 4.6 mm * y TI I TI I–II; AI I; x TI II; AI I; x




hurt by 2 nitinol
anchors, patch









4 Midmuscular, 4.8 mm * Lung edema 6 h
postoperative
z — —
5 Apical, 5.4 mm *; embolization
of 2 nitinol
anchors into lung
y z TI I; MI I; x TI I; x
6 Apical, 5.4 mm * y Bicuspid
aortic valve
AI I; TI I; MI I; x PI III
7 Apical, 5.0 mm * y AI I TI I; MI I; AI I; PI I; x TI I

















11 Midmuscular, 5.8 mm * y z AI I; TI I; $ MII; TI I; AI I
12 Midmuscular, 5.3 mm * Pneumothorax 14 d
postoperative
z — —
VSD, Ventricular septal defect; TI, tricuspid insufficiency; I, 1st degree; II, 2nd degree; MI, mitral insufficiency; AI, aortic insufficiency; PI, pulmonic insufficiency; III, 3rd
degree. *Successful implantation. yNo premature death. zNo pathology. xNo residual shunt.Although most animals had mild insufficiencies of the
tricuspid, mitral, and aortic valves, these insufficiencies
declined during the follow-up period. Furthermore, we mea-
sured FS to quantify cardiac function during our experi-
ments. Baseline FS value was 40.8%  5.0%. FS values
after 1 and 3 months were not reduced, indicating that car-
diac function was not impaired (42.8%  4.1% and
41.9%  6.5%). In addition, FS values (50.0%  9.2%)
with dobutamine after 3 months indicated good cardiac
function as well.
Pathologic Results
Animal 13 was killed perioperatively. Macroscopic and
microscopic evaluation of this heart 3 hours after creation
of an mVSD revealed a substantial defect, with fibrin cover-
age of the defect edges and significant hemorrhagic infiltra-
tion of the surrounding tissue (Figures 2, A and B, and 3, A
and B).
Animal 9 died 3 days after implantation. Correct place-
ment of the patch and its adequate fixation could be seen
on explantation; however, the tricuspid valve was infringed
with one anchor. In addition, macropathologic examination368 The Journal of Thoracic and Cardiovascular Surshowed a thin layer of reddish material on the surface of the
patch (Figure 2, C). Histopathologic analysis revealed
a typical pattern of fibrin condensation, with inclusion of
blood cells mainly around the patch (Figure 3, C and D).
Animal 10 died 14 days after implantation. Explantation
showed irregular coverage of the patch with a shiny, glisten-
ing, thin surface layer (Figure 2, D). Microscopic evaluation
revealed partial neoendothelialization of the patch and the
anchors. In addition, initial fibromuscular cellular ingrowth
integrated with thrombotic material could also be detected
within the defect (Figure 3, E and F).
Seven animals survived through the 3-month follow-up
period. Gross pathologic examination of these hearts re-
vealed correct placement of the patch in 6 of 7 explanted
hearts. In 1 heart, a slight and insignificant dislodgment of
the patch was detected.
All patches were completely covered by a glistening,
smooth, thin layer of neoendothelium with a thickness as
great as 1.6 mm. Continuity between the neoendothelium
over the patch and the surrounding septal wall was observed,
and anchors were completely overgrown by a transparent,
superficial tissue layer (Figure 2, E and F). Histopathologicgery c August 2009
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DFIGURE 2. Macroscopic evaluation. A and B, Explanted heart after creation of mVSD demonstrates substantial defect created with surrounding bleeding. A,
Overview; B, corresponding enlargement. C, Piece of septum from explanted heart 3 days after patch implantation. Thin layer of fibrin on surface of patch and
anchors is detectable. D, Patch and anchors 14 days after implantation. Irregular coverage of patch and anchors with shiny, glistening, thin surface layer. E and
F, Piece of septum from explanted heart after 3 months. Patch and anchors are completely overgrown by shiny, glistening surface layer. E, Overview; F,
corresponding enlargement.investigations showed ongoing cellular organization of the
surrounding septum, with only a few residual areas of
unorganized thrombotic tissue. Connective tissue containing
fibromuscular cells was predominant. In addition, vascular-
ization was beginning in the newly formed tissue (Figure 3,
G and H).
Immunohistochemical methods were used to characterize
different cellular components and showed antigen chara-
cteristics of fibromuscular cells (positive staining for smooth
muscle actin and vimentin; Figure 4, B and C). Superficial
cells to stained positively for von Willebrand factor
(Figure 4, A), which marked them as endothelial cells. Fi-
nally, SEM showed complete neoendothelial coverage of
the patch and the anchors (Figure 5).
Inflammatory Reactions
A mild to moderate inflammatory reaction was visible in
all specimens. In the heart explanted 3 days postoperatively,The Journal of Thoracic and Ccopious lymphocytes and a few granulocytes were detect-
able. Typical multinucleated foreign-body giant cells as
well as lymphocytes could be noticed adjacent to the textile
membrane of the implant after 14 days and after 3 months
(Figure 3, I). No superficial thrombus formation was found
in the specimens.
DISCUSSION
In this study, we demonstrated that with this hybrid tech-
nique we were able to close mVSD sufficiently without re-
sidual shunting or development of LV dysfunction in
a long-term porcine model. Both patch and anchors were
overgrown by endothelium and fibromuscular cells, with
continuity to the surrounding septal wall. Adequate integra-
tion of the patch and the anchors into the muscular septum
thus could be determined.
In general, hybrid therapy appears to be a reasonable
approach for treatment of mVSDs.1 Surgical andardiovascular Surgery c Volume 138, Number 2 369
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H
DFIGURE 3. Microscopic evaluation. A and B Microscopic evaluation of heart 3 hours after creation of mVSD. A, Creation of substantial defect, with fibrin
coverage of defect edges; B, significant hemorrhagic infiltration of myocardial tissue. C and D, Histopathologic analysis of patch and surrounding myocardial
tissue 3 days after implantation. Fibrin condensation with inclusion of blood cells mainly around polyester patch (P) can be detected. C, Overview; D, cor-
responding enlargement. E, Overview of patch 14 days after implantation. Partial neoendothelialization of patch and nitinol anchors (N) is visible. F, Begin-
ning ingrowth of fibromuscular cells around patch and anchors. G and H, Histopathologic investigation of patch and anchors after 3 months. G, Complete
neoendothelial coverage of patch and anchors with proceeding cellular organization of septum; H, enlargement showing fibromuscular cells and beginning of
vascularization. I, Typical multinucleated foreign-body giant cells in explant 3 months after implantation.370 The Journal of Thoracic and Cardiovascular Surgery c August 2009
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DFIGURE 4. Characteristic immunohistochemical staining after 3 months. Staining with antibodies against smooth muscle actin (A) and vimentin (B) dem-
onstrated formation of fibromuscular cells (brown color) mainly around patch material (P); von Willebrand factor staining (C, arrows) confirmed confluent
monolayer of cells on surface of patch to be endothelium.interventional therapies for mVSDs have different disadvan-
tages. Right-sided approaches may not allow correct visual-
ization of the defect, because it is often hidden by muscular
trabeculations.21 Left ventriculotomy may expose the defect
more easily on the smooth surface of the muscular septum,
but it is associated with such adverse side effects as LV dys-
function, arrhythmias, and apical aneurysms.6 Interventional
strategies may be limited by low patient weight or poor vas-
cular access. In small infants, the use of large sheaths may
cause rhythm disturbances, hemodynamic compromise, or
damage to the atrioventricular valve.1,11,12
Recently, there have been several reports of new hybrid
therapies for closure of mVSDs and perventricular closure
of mVSDs with an Amplatzer device.12,13,22 Advantages
of these approaches are the avoidance of transection of the
moderator band or other right ventricular muscle bundles,
avoidance of CPB, and lack of limitation by vascular access
or patient weight. Nevertheless, these hybrid therapies still
have disadvantages, such as device embolization or migra-
tion and development of atrioventricular blocks.12,13,22
We therefore developed a new hybrid therapy for mVSD
patch closure on the beating heart. Essentials of this hybrid
therapy are a patch delivery device consisting of a polyester
patch and a nitinol frame and a stapler system for fixation of
the nitinol anchors. These elements have already been used
by Vasilyev and colleagues17,18 for closure of atrial septal
defects and mVSDs. In our hybrid therapy, the patch system
was placed through the carotid artery into the LV and fixed
with 8 to 10 nitinol anchors through LV puncture. Finally,
the nitinol frame was detached from the patch. General fea-
sibility of our technique was shown in a short-term porcineThe Journal of Thoracic and Cmodel.16 Until now, it was not known whether our new
technique could close the mVSD sufficiently in the long
term, nor was it known how cardiac function, especially
LV function, would develop. We were also interested in
the integration of the patch and the anchors into the muscular
septum.
In this study, 2 of 12 pigs (17%) died as a result of failure
of the implantation technique. In the other animals (88%),
the mVSDs were successfully closed. Three of 12 animals
(25%) died of avoidable complications that were unrelated
to the device.
We believe that this study supports the general feasibility
of our technique. The 2 technical failures in our study were
mainly related to problems with echocardiography and cor-
rect visualization and orientation. We believe upcoming im-
provements in imaging techniques, such as development of
small tubes and holographic analysis, will lead to better re-
sults. Furthermore, training of the team is another important
factor in the success rate.23
In 1 animal we detected 2 embolized anchors in the lung.
For this reason, we modified our staplers with a 2-step re-
lease process to prevent the release of an anchor before it
is inside the patch. After that modification, embolization
of anchors was no longer observed.
We believe the LV approach to have some advantages rel-
ative to repair from the right ventricular side, such as better
identification of the defect and better alignment of the patch
because of the pressure gradient between the LV and the
right ventricle. Until now, however, LV approaches have
seldom been undertaken because of the risk of impaired
LV function.6,24 In our hybrid therapy, only minimal LVardiovascular Surgery c Volume 138, Number 2 371
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Dpuncture, approximately 2 mm in diameter, is needed. This
smaller puncture may be associated with a reduced risk of
LV dysfunction. Our measurements of FS, also with dobut-
amine, after 1 and 3 months showed no reduction in cardiac
function. In addition, an increase in PCWP could not be
seen during follow-up, also indicating good LV function.
In our experiments, development of a slight elevation in
PAPwas seen; however, this was probably not due to a resid-
ual mVSD. The procedure itself was quite traumatic to the
lungs in some experiments, especially because of the long
FIGURE 5. Characteristic scanning electron microscopy 3 months after
implantation demonstrates patch to be covered by confluent monolayer of
endothelial cells.372 The Journal of Thoracic and Cardiovascular Suoperative times. We learned in the meantime that operative
times could be significantly reduced with increasing experi-
ence. Two animals had pneumonia with elevated PAP,
which must be also considered in the evaluation of PAP.
Postinterventional echocardiography showed mild insuf-
ficiency of the mitral, tricuspid, or aortic valve in some ani-
mals. Most insufficiencies of the atrioventricular valves
decreased or vanished during the follow-up period. Struc-
tural damage to the valves was not seen. The insufficiency
of the atrioventricular valves may have been due to the use
of large sheaths. Consequently, techniques that do not
need to pass the aortic valve would be preferable.
We performed histologic examinations on all explanted
hearts, including those of animals that were killed early
and those that completed the study through the follow-up
period. In all hearts, macroscopic pathologic examination
showed correct placement of the patch. In addition, adequate
fixation of the patch could be detected, with no dislocation
seen in any of the animals. Trivial residual shunting was no-
ticed in just 1 animal during the follow-up period. These
findings demonstrate that our technique was able to close
the mVSDs sufficiently.
We performed investigations at different time points to
demonstrate progressive coverage of the patch. Formation
of a fibrin net with inclusion of blood cells on the surface
of the polyester exposed to the blood could be detected by
3 days, followed by cells spreading over the fibrin net by
14 days. After 3 months, a confluent monolayer of cells,
which could be identified as endothelial cells in immunohis-
tochemical and SEM examinations, could be demonstrated
in all specimens. Additionally, cellular organization pro-
ceeded in the first month after implantation with ingrowths
of fibromuscular cells and the formation of loosely arranged
vascular tissue. This is consistent with reports in the litera-
ture about the biocompatibility of cardiovascular implants,
which described corresponding steps.25-27
The anchors were also completely overgrown by endothe-
lium, indicating good integration of the patch into the mus-
cular septum. Finally, superficial deposition of thrombotic
material was not seen in any of the specimens.
A mild to moderate inflammatory reaction could be de-
tected at the implantation site. Lymphocytic infiltration
was found adjacent to the patch, indicating a persistent in-
flammatory reaction. Furthermore, foreign-body giant cells
could be detected in our specimens and were considered to
be part of the normal wound healing response. These reac-
tions have also been described for various cardiovascular
implants.25-27
Study Limitations
Our study was limited first because the defects were
created iatrogenically, as opposed to being congenital
defects. The procedure to create the defect was quite trau-
matic to the myocardium, as seen in the macroscopic andrgery c August 2009
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Dmicroscopic evaluation. This may have altered the healing
and immune responses after patch implantation. Second, in
terms of the long-term prospects for LV function, the im-
plantation time of 3 months was short relative to the possible
implantation time in human patients.
CONCLUSIONS
In conclusion, we demonstrated that with this new kind of
hybrid approach mVSDs can be closed without patch dislo-
cation through long-term follow-up. Global cardiac function
was not reduced, and the patch was well integrated into the
muscular septum. Finally, this study also confirmed satisfac-
tory histologic findings for the polyester patch at different
time points. Further improvement of the technique is neces-
sary, however, before human use can be considered.
We thank Rabea Hinkel and Eckart Thein for critical comments
on the manuscript.
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